Takeda Pharmaceutical Crecimiento futuro

Future controles de criterios 2/6

Takeda Pharmaceutical se prevé un crecimiento anual de los beneficios y los ingresos de 20.3% y 0.3% respectivamente. Se prevé que el BPA sea de grow en 19.4% al año. Se prevé que la rentabilidad de los fondos propios sea de 5.9% en 3 años.

Información clave

19.0%

Tasa de crecimiento de los beneficios

18.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	21.0%
Tasa de crecimiento de los ingresos	0.8%
Rentabilidad financiera futura	6.0%
Cobertura de analistas	Good
Última actualización	15 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:TKPH.F - Estimaciones futuras de los analistas y datos financieros pasados (JPY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	4,172,767	343,416	709,270	1,071,445	9
3/31/2026	4,076,263	297,526	669,148	1,041,034	17
3/31/2025	3,993,260	236,142	671,310	1,031,225	18
3/31/2024	4,070,761	143,036	359,477	886,813	18
12/31/2023	4,169,049	178,219	-129,035	731,449	N/A
9/30/2023	4,154,414	191,626	129,243	963,227	N/A
6/30/2023	4,113,631	301,398	180,765	985,315	N/A
3/31/2023	4,027,478	317,017	343,467	977,156	N/A
12/31/2022	3,944,611	274,525	817,615	1,059,047	N/A
9/30/2022	3,749,354	213,167	789,089	1,028,328	N/A
6/30/2022	3,591,868	197,389	798,367	1,040,488	N/A
3/31/2022	3,569,006	230,059	937,068	1,123,105	N/A
12/31/2021	3,465,991	438,515	902,309	1,148,481	N/A
9/30/2021	3,401,450	473,105	777,572	1,018,931	N/A
6/30/2021	3,345,565	431,178	793,645	1,031,928	N/A
3/31/2021	3,197,812	376,005	774,463	1,010,931	N/A
12/31/2020	3,199,240	180,631	608,015	795,408	N/A
9/30/2020	3,221,804	56,051	498,511	720,676	N/A
6/30/2020	3,243,917	119,743	479,618	694,824	N/A
3/31/2020	3,291,188	44,241	452,042	669,752	N/A
12/31/2019	3,236,697	13,275	402,421	601,798	N/A
9/30/2019	2,876,782	83,262	399,600	551,732	N/A
6/30/2019	2,496,511	63,959	266,965	408,797	N/A
3/31/2019	2,097,224	135,192	194,365	328,479	N/A
12/31/2018	1,780,976	110,414	221,992	336,742	N/A
9/30/2018	1,769,726	140,738	225,190	328,658	N/A
6/30/2018	1,772,125	120,339	207,862	343,761	N/A
3/31/2018	1,770,531	186,886	249,592	377,854	N/A
12/31/2017	1,785,773	190,172	234,852	376,566	N/A
9/30/2017	1,762,667	163,457	N/A	316,619	N/A
6/30/2017	1,746,286	160,202	N/A	285,157	N/A
3/31/2017	1,732,051	114,940	N/A	261,363	N/A
12/31/2016	1,729,967	132,194	N/A	-8,176	N/A
9/30/2016	1,754,130	150,081	N/A	42,293	N/A
6/30/2016	1,795,088	155,110	N/A	57,618	N/A
3/31/2016	1,807,378	80,166	N/A	25,491	N/A
12/31/2015	1,831,096	-111,874	N/A	203,553	N/A
9/30/2015	1,830,521	-152,827	N/A	192,836	N/A
6/30/2015	1,812,971	-154,591	N/A	189,123	N/A
3/31/2015	1,777,824	-145,775	N/A	182,517	N/A
12/31/2014	1,744,795	75,405	N/A	N/A	N/A
9/30/2014	1,714,694	103,390	N/A	240,094	N/A
6/30/2014	1,692,531	110,981	N/A	N/A	N/A
3/31/2014	1,691,685	106,658	N/A	148,335	N/A
12/31/2013	1,655,033	103,330	N/A	N/A	N/A
9/30/2013	1,598,674	76,159	N/A	120,224	N/A
6/30/2013	1,569,277	72,757	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: TKPH.F(22.2% al año) es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: TKPH.FSe prevé que los beneficios de la empresa (22.2% al año) crezcan más deprisa que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de TKPH.F crezcan, pero no significativamente.

Ingresos vs. Mercado: TKPH.F(0.3% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: TKPH.FSe prevé que los ingresos de la empresa (0.3% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: TKPH.FSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (5.9%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Takeda Pharmaceutical Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Revised Earnings Guidance for the Full Year of 2022

Recent updates

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda Pharmaceutical Company Limited Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura

Takeda’S Phase 3 Aurora Study Provides Evidence of Maribavir’S Clinically Meaningful and Durable Effect in Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

Takeda's Qdenga(R) Dengue Tetravalent Vaccine [Live, Attenuated]) Approves for Use in European Union

Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration Accept and Grant Priority Review of the Biologics License Application for TAK-003

Takeda Announces Phase 3 Trial of Iclusig (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, Setting with No Targeted Treatments Approved in the US

Takeda Announces European Commission Approves LIVTENCITY (Maribavir) for Treatment of Adults with Post-Transplant Cytomegalovirus Infection and/or Disease that are Refractory (with or without Resistance) to One or More Prior Therapies

Takeda Pharmaceutical Company Limited to Report Q3, 2023 Results on Feb 02, 2023

Takeda Pharmaceutical Company Limited Revised Earnings Guidance for the Full Year of 2022

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

U.S. Food and Drug Administration Accepts Takeda Pharmaceutical Company Limited's Supplemental Biologics License Application for Use of TAKHZYRO to Prevent Hereditary Angioedema Attacks in Children 2 Years of Age and Older

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-Transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

Takeda Launches CDPath, A Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease

Takeda’s QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) Approves in Indonesia for Use Regardless of Prior Dengue Exposure

Takeda Pharmaceutical Company Limited to Report Q2, 2023 Results on Oct 27, 2022

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento